M. Alexander Otto on Muck Rack

M. Alexander Otto

Verified
Seattle
As seen in: Medscape, Medscape Duestch, Medscape France, Medscape Noticias Médicas, Medscape PT, Tacoma News Tribune, Clinical Neurology News, Internal Medicine News, MDEdge, MDedge | Cardiology News, MDedge |Psychiatry and
Physician assistant, journalist. Over 20 years covering medicine. MIT journalism fellow, WebMD reporter. McClatchy, Bloomberg BNA, Washington Post background.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with M. Alexander

Contact M. Alexander, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Q&A: Can More Patients With MIBC Keep Their Bladder?

|
By M. Alexander Otto Verified
| Medscape Verified
Bladder preservation in muscle-invasive bladder cancer (MIBC) may be entering a new era. For years, the standard of care for appropriate candidates with MIBC has been trimodal therapy (TMT): maximal transurethral resection and chemoradiation, followed by surveillance for clinical complete responders and salvage cystectomy for local recurrence. About half of the patients are alive and still have their bladder at 5 years, and the results haven’t improved much over time.
Open in Who Shared Issue with article?

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

|
By M. Alexander Otto Verified
| Medscape Verified
The FDA has approved Orca-T (Tregzi, Orca Bio) for use in matched-donor hematopoietic stem cell transplants (HSCTs) with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-vs-host-disease (GVHD)-free survival in adults with hematologic malignancies. Orca-T is a specialized stem cell transplant designed specifically to reduce the risk for chronic GVHD.
Open in Who Shared Issue with article?

Sacituzumab Govitecan Gains First-Line TNBC Indications

|
By M. Alexander Otto Verified
| Medscape Verified
The FDA has approved two first-line indications for sacituzumab govitecan (Trodelvy, Gilead Sciences) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). One of the indications is for use as a single agent for patients who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. The second is for use in combination with pembrolizumab or subcutaneous pembrolizumab for patients whose tumors express PD-L1 as determined by an FDA-authorized test.
Open in Who Shared Issue with article?
See all 1,555 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified